Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71


Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients.

Wagner G, Osilla KC, Garnett J, Ghosh-Dastidar B, Bhatti L, Witt M, Goetz MB.

J Int Assoc Physicians AIDS Care (Chic). 2012 Jul-Aug;11(4):245-51. doi: 10.1177/1545109712444163. Epub 2012 May 7.


Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.

Osilla KC, Wagner G, Garnett J, Ghosh-Dastidar B, Witt M, Bhatti L, Goetz MB.

AIDS Patient Care STDS. 2011 Sep;25(9):533-8. doi: 10.1089/apc.2011.0048. Epub 2011 Aug 8.


Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection.

Wagner G, Ryan G, Osilla KC, Bhatti L, Goetz M, Witt M.

AIDS Patient Care STDS. 2009 Sep;23(9):715-25. doi: 10.1089/apc.2009.0049.


Awareness of hepatitis C infection among women with and at risk for HIV.

Cohen MH, Grey D, Cook JA, Anastos K, Seaberg E, Augenbraun M, Burian P, Peters M, Young M, French A.

J Gen Intern Med. 2007 Dec;22(12):1689-94. Epub 2007 Oct 9.


Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment.

Osilla KC, Ryan G, Bhatti L, Goetz M, Witt M, Wagner G.

AIDS Patient Care STDS. 2009 Dec;23(12):993-9. doi: 10.1089/apc.2009.0153.


Low prevalence of hepatitis C co-infection in recently HIV-infected minority men who have sex with men in Los Angeles: a cross-sectional study.

Chew KW, Blum ML, Javanbakht M, Clare LE, Bornfleth LD, Bolan R, Bhattacharya D, Gorbach PM.

BMC Infect Dis. 2015 Nov 20;15:538. doi: 10.1186/s12879-015-1279-z.


Impact of hepatitis B and C co-infection on health-related quality of life in HIV positive individuals.

Gillis J, Cooper C, Rourke S, Rueda S, O'Brien K, Collins E, Rachlis A, Hart TA, Raboud J; OHTN Cohort Study Group.

Qual Life Res. 2013 Sep;22(7):1525-35. doi: 10.1007/s11136-012-0283-7. Epub 2012 Oct 17.


Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.

Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T.

JAMA. 2015 Mar 24-31;313(12):1223-31. doi: 10.1001/jama.2015.1328.


Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status.

Marcus JL, Leyden WA, Chao CR, Xu L, Quesenberry CP Jr, Tien PC, Klein DB, Towner WJ, Horberg MA, Silverberg MJ.

AIDS Patient Care STDS. 2015 Jul;29(7):370-8. doi: 10.1089/apc.2015.0040. Epub 2015 May 18.


Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons.

Thompson VV, Ragland KE, Hall CS, Morgan M, Bangsberg DR.

AIDS. 2005 Oct;19 Suppl 3:S208-14.


Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival.

Chen M, Wong WW, Law MG, Kiertiburanakul S, Yunihastuti E, Merati TP, Lim PL, Chaiwarith R, Phanuphak P, Lee MP, Kumarasamy N, Saphonn V, Ditangco R, Sim BL, Nguyen KV, Pujari S, Kamarulzaman A, Zhang F, Pham TT, Choi JY, Oka S, Kantipong P, Mustafa M, Ratanasuwan W, Durier N, Chen YM.

PLoS One. 2016 Mar 2;11(3):e0150512. doi: 10.1371/journal.pone.0150512. eCollection 2016.


Psychosocial correlates of HIV-monoinfection and HIV/HCV-coinfection among men who have sex with men.

Pantalone DW, Hessler DM, Bankoff SM, Shah BJ.

J Behav Med. 2012 Oct;35(5):520-8. doi: 10.1007/s10865-011-9381-1. Epub 2011 Sep 23.


Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients.

Tural C, Fuster D, Tor J, Ojanguren I, Sirera G, Ballesteros A, Lasanta JA, Planas R, Rey-Joly C, Clotet B.

J Viral Hepat. 2003 Mar;10(2):118-25.


Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life.

Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, Pol S.

J Viral Hepat. 2006 Oct;13(10):678-82.


Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).

Dold L, Ahlenstiel G, Althausen E, Luda C, Schwarze-Zander C, Boesecke C, Wasmuth JC, Rockstroh JK, Spengler U.

PLoS One. 2015 Aug 4;10(8):e0134158. doi: 10.1371/journal.pone.0134158. eCollection 2015.


Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.

Roux P, Fugon L, Winnock M, Salmon-Céron D, Lacombe K, Sogni P, Spire B, Dabis F, Carrieri MP; ANRS-CO-13-HEPAVIH Study Group.

Addiction. 2012 Jan;107(1):152-9. doi: 10.1111/j.1360-0443.2011.03608.x. Epub 2011 Oct 12.


Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response.

Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M.

Liver Int. 2013 Aug;33(7):999-1007. doi: 10.1111/liv.12150. Epub 2013 Mar 20.


Seroprevalence of hepatitis C infection in HIV patients using a rapid one-step test strip kit.

Akinbami AA, Oshinaike OO, Adeyemo TA, Adediran A, Oshikomaiya BI, Ismail KA.

Nig Q J Hosp Med. 2010 Jul-Sep;20(3):144-6.


Supplemental Content

Support Center